Status:
WITHDRAWN
Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Schizophrenia
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This study will evaluate the safety of multiple doses of NSA-789 in subjects with schizophrenia or schizoaffective disorder. This study will also assess how NSA-789 is absorbed and eliminated, and its...
Eligibility Criteria
Inclusion
- Inclusion:
- Men or women of non childbearing potential (WONCBP) aged 18 to 50 years, inclusive.
- Currently under the care of a physician for psychiatric illness.
- Clinical diagnosis of schizophrenia or schizo affective disorder in the opinion of the study psychiatrist based on review of all available clinical data.
- Exclusion:
- Any unstable medical or psychiatric condition, which may prevent the successful and safe completion of the study.
Exclusion
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00892021
Start Date
May 1 2009
End Date
October 1 2009
Last Update
August 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rockville, Maryland, United States, 20850